CytomX Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2024 | 2 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2024 | 6 | -$0.26 | -$0.10 | -$0.17 |
| Q4 2024 | 2 | -$0.22 | -$0.22 | -$0.22 |
| Q1 2025 | 5 | -$0.14 | -$0.14 | -$0.14 |
| Q2 2025 | 5 | -$0.15 | -$0.15 | -$0.15 |
| Q3 2025 | 5 | -$0.14 | -$0.14 | -$0.14 |
| Q4 2025 | 5 | -$0.22 | -$0.22 | -$0.22 |
| Q1 2026 | 2 | -$0.28 | -$0.28 | -$0.28 |
| Q2 2026 | 2 | -$0.28 | -$0.28 | -$0.28 |
| Q3 2026 | 2 | -$0.29 | -$0.29 | -$0.29 |
| Q4 2026 | 2 | -$0.30 | -$0.30 | -$0.30 |
CytomX Therapeutics, Inc. Earnings Date And Information
CytomX Therapeutics, Inc. last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.08 earnings per share for the quarter, missing analysts' consensus estimates of $-0.07 by $0.01. The company had revenue of 25.12 M for the quarter and had revenue of 101.21 M for the year. CytomX Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.0077 diluted earnings per share) and currently has a price-to-earnings ratio of 7.66. CytomX Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
CytomX Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/08/2024 | Q2 2024 | -$0.07 | -$0.08 | -0.01 | $20.00 M | $25.12 M |
| 05/08/2024 | Q1 2024 | -$0.08 | $0.17 | 0.25 | $41.46 M | |
| 03/11/2024 | Q4 2023 | $0.00 | $0.01 | 0.01 | $26.61 M | |
| 11/07/2023 | Q3 2023 | -$0.19 | $0.04 | 0.23 | $13.34 M | $26.38 M |
| 08/08/2023 | Q2 2023 | -$0.19 | -$0.02 | 0.17 | $13.68 M | $24.72 M |
| 05/09/2023 | Q1 2023 | -$0.16 | -$0.01 | 0.15 | $23.50 M | |
| 03/27/2023 | Q4 2022 | -$0.21 | -$0.40 | -0.19 | $946,000 | |
| 11/08/2022 | Q3 2022 | -$0.32 | -$0.34 | -0.02 | $18.15 M | $16.92 M |
| 08/04/2022 | Q2 2022 | -$0.36 | -$0.36 | 0 | $18.11 M | $18.17 M |
| 05/05/2022 | Q1 2022 | -$0.35 | -$0.36 | -0.01 | $17.14 M | |
| 03/01/2022 | Q4 2021 | -$0.25 | -$0.40 | -0.15 | $19.73 M | |
| 11/04/2021 | Q3 2021 | -$0.30 | -$0.35 | -0.05 | $18.38 M | $17.59 M |
| 08/05/2021 | Q2 2021 | -$0.26 | -$0.30 | -0.04 | $16.96 M | $16.29 M |
| 05/06/2021 | Q1 2021 | -$0.29 | -$0.26 | 0.03 | $15.97 M | |
| 02/24/2021 | Q4 2020 | -$0.35 | -$0.32 | 0.03 | $16.37 M | |
| 11/05/2020 | Q3 2020 | -$0.36 | -$0.32 | 0.04 | $17.14 M | $17.79 M |
| 08/06/2020 | Q2 2020 | $0.34 | -$0.34 | -0.68 | $52.99 M | $16.61 M |
| 05/07/2020 | Q1 2020 | -$0.46 | $0.27 | 0.73 | $49.59 M | |
| 02/27/2020 | Q4 2019 | -$0.55 | -$0.78 | -0.23 | $8.28 M | |
| 11/07/2019 | Q3 2019 | -$0.39 | -$0.52 | -0.13 | $18.07 M | $10.71 M |
CytomX Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is CytomX Therapeutics, Inc.'s earnings date?
CytomX Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
How can I listen to CytomX Therapeutics, Inc.'s earnings conference call?
The conference call for CytomX Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read CytomX Therapeutics, Inc.'s conference call transcript?
The conference call transcript for CytomX Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does CytomX Therapeutics, Inc. generate each year?
CytomX Therapeutics, Inc. (:CTMX) has a recorded annual revenue of $101.21 M.
-
How much profit does CytomX Therapeutics, Inc. generate each year?
CytomX Therapeutics, Inc. (:CTMX) has a recorded net income of $101.21 M. CytomX Therapeutics, Inc. has generated $-0.0077 earnings per share over the last four quarters.
-
What is CytomX Therapeutics, Inc.'s price-to-earnings ratio?
CytomX Therapeutics, Inc. (:CTMX) has a price-to-earnings ratio of 7.66 and price/earnings-to-growth ratio is -0.26.
